Evidence / notes and sources
Research is a start. Results matter.
Were people given MOTS-c, or did a study only measure what their bodies made? That question changes what a result can tell you.
Look for what was tested, who was studied and what was found.
Read the short answerRead past the word “study”
- Cells & mice
Mice given MOTS-c gained less weight and handled sugar better.
- Measurements in people
The body’s own MOTS-c
- A treatment study of MOTS-c
Awaiting results
The misconception
“A human study proves it works.”
- What it can sound like
- The words “human study” can sound like proof that an injection helps.
- The short answer
As of September 2026, no published treatment study shows what happens when people are given MOTS-c itself.
Hoped-for weight and blood sugar benefits remain unproven in people.
Measuring what a body makes and testing a treatment answer different questions.
Read the findings
What each kind of study can tell you
What happened in mice?
Mice given MOTS-c gained less weight and handled sugar better in the first published study.
A mouse result does not establish the same benefit in people.
What did human studies measure?
Human measurement studies looked at MOTS-c made within the body.
A link between the amount of MOTS-c in the blood and a person’s weight or fitness does not show that taking MOTS-c will help.
Does a study plan count as a result?
As of September 2026, the study testing MOTS-c itself in people was still looking for people to join.
It had no results posted.
A study’s recorded plan says what researchers intend to test; it does not show whether the treatment helps.
What about the separate, finished study of CB4211?
That separate study tested CB4211, a different, company-made version based on MOTS-c.
It tested CB4211 rather than MOTS-c itself.
As of September 2026, its results had not appeared in a medical journal or in the public study record.
Does “natural” settle the question?
The body makes MOTS-c, but that does not establish the safety of a lab-made injection.
An immune reaction is when the body’s defences treat a substance as an invader.
In its review prepared for July 2026, the FDA flagged a possible immune reaction to injected MOTS-c.
This is a potential risk, not a measured rate of reactions in patients.
As of September 2026, human safety risks and long-term treatment effects remain unknown.